BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 15, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

PA-824: Phase II started

The TB Alliance began a double-blind, South African Phase II trial in 68 patients to evaluate TMC207, PA-824 and moxifloxacin for 14 days. Patients will receive TMC207 (700 mg on day 1,500 mg on day 2 and 400 mg on days 3-14) alone; TMC207 plus pyrazinamide; once-daily 200 mg PA-824 plus pyrazinamide; PA-824...

Read the full 253 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >